


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app16.us.archive.org';v.server_ms=295;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180713063019im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180713063019im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180713063019im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180713063019im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180713063019/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180713063019im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180713063019cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713063019js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180713063019if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713063019/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180713063019if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713063019/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180713063019/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180713063019/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180713063019/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180713063019/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180713063019/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180713063019/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180713063019/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180713063019/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180713063019/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180713063019/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180713063019/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180713063019/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180713063019/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180713063019/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180713063019/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180713063019/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180713063019/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180713063019/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713063019/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010874</li>
            <li>2015 Dec 8
            </li>            
                                </ul>
        <div>
                <h1>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180713063019/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20Academy%20of%20Neurology&amp;fLockTerm=American%2BAcademy%2Bof%2BNeurology">American Academy of Neurology</a></li>
                        <li>   
                                <a id="39" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2015 Dec 8;85(23):2063-71. [40 references] <a href="https://web.archive.org/web/20180713063019/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26644048" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=fulltextlink&amp;redirect=https%253a%252f%252fwww.aan.com%252fGuidelines%252f">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180713063019/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180713063019/https://www.guideline.gov/search?f_MSH_CUI=C0007812&amp;fLockTerm=Cerebrospinal+Fluid+Shunts">Cerebrospinal Fluid Shunts</a>
, <a href="/web/20180713063019/https://www.guideline.gov/search?f_MSH_CUI=C0020258&amp;fLockTerm=Hydrocephalus%2c+Normal+Pressure">Hydrocephalus, Normal Pressure</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180713063019/https://www.guideline.gov/search?f_MTH_CUI=C0007812&amp;fLockTerm=Cerebrospinal+fluid+shunts+procedure">Cerebrospinal fluid shunts procedure</a>
, <a href="/web/20180713063019/https://www.guideline.gov/search?f_MTH_CUI=C0020258&amp;fLockTerm=Hydrocephalus%2c+Normal+Pressure">Hydrocephalus, Normal Pressure</a>
, <a href="/web/20180713063019/https://www.guideline.gov/search?f_MTH_CUI=C0728823&amp;fLockTerm=Ventricular+shunt+device">Ventricular shunt device</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180713063019/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007812&amp;fLockTerm=Creation+of+cerebrospinal+fluid+shunt">Creation of cerebrospinal fluid shunt</a>
 (119566000), <a href="/web/20180713063019/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0183288&amp;fLockTerm=Hydrocephalic+shunt+catheter">Hydrocephalic shunt catheter</a>
 (7733008), <a href="/web/20180713063019/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0277553&amp;fLockTerm=Idiopathic+disease">Idiopathic disease</a>
 (41969006), <a href="/web/20180713063019/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0020258&amp;fLockTerm=Normal+pressure+hydrocephalus">Normal pressure hydrocephalus</a>
 (30753002), <a href="/web/20180713063019/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0728823&amp;fLockTerm=Ventricular+shunt">Ventricular shunt</a>
 (258593008)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180713063019/https://www.guideline.gov/search?f_UMD_CUI=C0183288&amp;fLockTerm=Shunts%2c+Hydrocephalic">Shunts, Hydrocephalic</a>
 (16-244), <a href="/web/20180713063019/https://www.guideline.gov/search?f_UMD_CUI=C1741052&amp;fLockTerm=Shunts%2c+Hydrocephalic%2c+Total">Shunts, Hydrocephalic, Total</a>
 (13-587)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/downloadcontent/ngc-10874?contentType=pdf" class="pdf">.PDF 110.0 kb</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/downloadcontent/ngc-10874?contentType=word" class="word">Word Document 305.7 kb</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/downloadcontent/ngc-10874?contentType=xml" class="xml">.XML 50.9 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180713063019/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713063019/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713063019/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180713063019/mailto:/?Subject=AHRQ: Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.&amp;body=https://www.guideline.gov/summaries/summary/49957/practice-guideline-idiopathic-normal-pressure-hydrocephalus-response-to-shunting-and-predictors-of-response-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2015 Dec 08. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=enw">EndNote</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=txt">Medlars</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=ris">ProCite</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957">RefWorks</a></li>
                            <li><a href="/web/20180713063019/https://www.guideline.gov/summaries/citedownload/49957?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="49957" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions of the levels of the recommendations (<strong>A</strong>, <strong>B</strong>, <strong>C</strong>, <strong>U</strong>) and classification of the evidence (<strong>Class I-IV</strong>) are provided at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Recommendations</strong></span></p>
<ul style="list-style-type: disc;">
    <li>Clinicians may choose to offer shunting as a treatment for patients with idiopathic normal pressure hydrocephalus (iNPH) in order to treat their subjective symptoms of iNPH and gait (<strong>Level C</strong>). </li>
    <li>Because there is a risk of significant adverse events (AEs), the risks and benefits of the procedure should be carefully weighed (<strong>Level B</strong>). </li>
    <li>Clinicians should inform patients with iNPH with elevated R<sub>o</sub> that they have an increased chance of responding to shunting compared with those without such elevation (<strong>Level B</strong>). </li>
    <li>Clinicians may counsel patients with iNPH that an abnormal CSF infusion test (CSF-IT) or a positive response to repeated lumbar punctures (LPs) increases the chance of response to shunting (<strong>Level C</strong>). </li>
    <li>Clinicians may counsel patients with iNPH and their families that increasing age does not necessarily decrease the chance of a shunt being successful (<strong>Level C</strong>). </li>
    <li>Clinicians may counsel patients with suspected iNPH and with impaired cerebral blood flow (CBF) reactivity to acetazolamide, measured by single-photon emission computed tomography (SPECT), that they are possibly more likely to respond to shunting (<strong>Level C</strong>). </li>
</ul>
<p><strong><span style="text-decoration: underline;">Definitions</span></strong></p>
<p><strong>Evidence Schemes for Classifying Articles</strong></p>
<p><em>Therapeutic Scheme</em></p>
<p><span style="text-decoration: underline;">Class I</span></p>
<ul style="list-style-type: disc;">
    <li>Randomized, controlled clinical trial (RCT) in a representative population </li>
    <li>Masked or objective outcome assessment </li>
    <li>Relevant baseline characteristics are presented and substantially equivalent between treatment groups, or there is appropriate statistical adjustment for differences </li>
    <li>Also required:
    <ol style="list-style-type: lower-alpha;" start="1">
        <li>Concealed allocation </li>
        <li>Primary outcome(s) clearly defined </li>
        <li>Exclusion/inclusion criteria clearly defined </li>
        <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias </li>
        <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
        <ol style="list-style-type: decimal;" start="1">
            <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority </li>
            <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective) </li>
            <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment </li>
            <li>The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossovers </li>
        </ol>
        </li>
    </ol>
    </li>
</ul>
<p><span style="text-decoration: underline;">Class II</span></p>
<ul style="list-style-type: disc;">
    <li>Cohort study meeting criteria a&ndash;e above or an RCT that lacks one or two criteria b&ndash;e </li>
    <li>All relevant baseline characteristics are presented and substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences </li>
    <li>Masked or objective outcome assessment </li>
</ul>
<p><span style="text-decoration: underline;">Class III</span></p>
<ul style="list-style-type: disc;">
    <li>Controlled studies (including studies with external controls such as well-defined natural history controls) </li>
    <li>A description of major confounding differences between treatment groups that could affect outcome** </li>
    <li>Outcome assessment masked, objective, or performed by someone who is not a member of the treatment team </li>
</ul>
<p><span style="text-decoration: underline;">Class IV</span></p>
<ul style="list-style-type: disc;">
    <li>Did not include patients with the disease </li>
    <li>Did not include patients receiving different interventions </li>
    <li>Undefined or unaccepted interventions or outcome measures </li>
    <li>No measures of effectiveness or statistical precision presented or calculable </li>
</ul>
<p class="Note">*Numbers 1&ndash;3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data)</p>
<p><em>Prognostic Scheme</em></p>
<p><span style="text-decoration: underline;">Class I</span></p>
<p>A cohort study of a broad spectrum of persons at risk for developing the outcome (e.g., target disease, work status). The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who is masked to the presence of the risk factor. Study results allow calculation of measures of prognostic accuracy.</p>
<p><span style="text-decoration: underline;">Class II</span></p>
<p>A case-control study of a broad spectrum of persons with the condition compared to a broad spectrum of controls or a cohort study of a broad spectrum of persons at risk for the outcome (e.g., target disease, work status) where the data was collected retrospectively. The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who is masked to the presence of the risk factor. Study results allow calculation of measures of prognostic accuracy.</p>
<p><span style="text-decoration: underline;">Class III</span></p>
<p>A case-control study or a cohort study where either the persons with the condition or the controls are of a narrow spectrum where the data was collected retrospectively. The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who did not determine the presence of the risk factor. Study results allow calculation of measures of a prognostic accuracy.</p>
<p><span style="text-decoration: underline;">Class IV</span></p>
<p>Studies not meeting Class I, II, or III criteria, including consensus, expert opinion, or a case report.</p>
<p><strong>Classification of Recommendations</strong></p>
<p><strong>A</strong> = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>C</strong> = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Idiopathic normal pressure hydrocephalus (iNPH)</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Counseling</p>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Neurological Surgery</p>
                    <p>Neurology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To evaluate evidence for utility of shunting in idiopathic normal pressure hydrocephalus (iNPH) and for predictors of shunting effectiveness</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Patients with idiopathic normal pressure hydrocephalus (iNPH)</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><ol style="list-style-type: decimal;" start="1">
    <li>Ventricular shunting </li>
    <li>Consideration of risk of significant adverse effects (weighing risks vs. benefits) </li>
    <li>Counseling and informing patients/families that:
    <ul style="list-style-type: disc;">
        <li>Elevated R<sub>o</sub> increases chance of responding to shunting compared with those without elevation </li>
        <li>External lumbar drainage or to repeated lumbar punctures increases chance of response to shunting </li>
        <li>Increasing age does not decrease the chance of successful shunting </li>
    </ul>
    </li>
</ol></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Interview-Based Impression of Change, plus interview (CIBIC-Plus) assessment of global ratings </li>
    <li>Cognitive, balance, gait, and urinary functioning </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>The panel performed an initial search of MEDLINE, EMBASE, LILACS, and the Cochrane Database from 1980 to September 2012, limited to English-language publications, using the search terms ("normal pressure hydrocephalus" or "NPH" or "adult hydrocephalus syndrome" or "hydrocephalus") and ("shunting" or "treatment") and ("trial" or "outcome" or "predictors" or "response") and "neurosurgery." The search identified 438 citations. The panel performed an updated search of MEDLINE and Cochrane from 2012 to November 2013 using ("normal pressure hydrocephalus" or "NPH") and filtering manually with terms of initial search. Subsequent to this update, 2 additional relevant studies were published and are included. The panel excluded case reports, editorials, meta-analyses, review articles, duplicative reports, and articles regarding only secondary normal pressure hydrocephalus (NPH), including fewer than 10 patients with idiopathic NPH (iNPH) or suspected iNPH (as smaller numbers would lack statistical power), using no comparison group, or following patients for response to therapy for less than 3 months. At least 2 reviewers working independently of each other screened each of the remaining abstracts for relevance. If discordant conclusions could not be resolved by consensus, the panel included a third reviewer. Two panelists reviewed in detail the articles considered relevant to either of the questions, using pre-established criteria for relevance.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>This selection process yielded a total of 36 articles. There were 3 Class I, 8 Class II, and 7 Class III studies relevant to the prognostic question. Three Class III studies were identified for the therapeutic question. All remaining articles had Class IV evidence.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Evidence Schemes for Classifying Articles</span></strong></p>
<p><strong>Therapeutic Scheme</strong></p>
<p><em>Class I</em></p>
<ul style="list-style-type: disc;">
    <li>Randomized, controlled clinical trial (RCT) in a representative population </li>
    <li>Masked or objective outcome assessment </li>
    <li>Relevant baseline characteristics are presented and substantially equivalent between treatment groups, or there is appropriate statistical adjustment for differences </li>
    <li>Also required:
    <ol style="list-style-type: lower-alpha;" start="1">
        <li>Concealed allocation </li>
        <li>Primary outcome(s) clearly defined </li>
        <li>Exclusion/inclusion criteria clearly defined </li>
        <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias </li>
        <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
        <ol style="list-style-type: decimal;" start="1">
            <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority </li>
            <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose, and dosage adjustments are similar to those previously shown to be effective) </li>
            <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment </li>
            <li>The interpretation of the study results is based on a per-protocol analysis that accounts for dropouts or crossovers </li>
        </ol>
        </li>
    </ol>
    </li>
</ul>
<p><em>Class II</em></p>
<ul style="list-style-type: disc;">
    <li>Cohort study meeting criteria a&ndash;e above or an RCT that lacks one or two criteria b&ndash;e </li>
    <li>All relevant baseline characteristics are presented and substantially equivalent among treatment groups, or there is appropriate statistical adjustment for differences </li>
    <li>Masked or objective outcome assessment </li>
</ul>
<p><em>Class III</em></p>
<ul style="list-style-type: disc;">
    <li>Controlled studies (including studies with external controls such as well-defined natural history controls) </li>
    <li>A description of major confounding differences between treatment groups that could affect outcome** </li>
    <li>Outcome assessment masked, objective, or performed by someone who is not a member of the treatment team </li>
</ul>
<p><em>Class IV</em></p>
<ul style="list-style-type: disc;">
    <li>Did not include patients with the disease </li>
    <li>Did not include patients receiving different interventions </li>
    <li>Undefined or unaccepted interventions or outcome measures </li>
    <li>No measures of effectiveness or statistical precision presented or calculable </li>
</ul>
<p class="Note">*Numbers 1&ndash;3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data)</p>
<p><strong>Prognostic Scheme</strong></p>
<p><em>Class I</em></p>
<p>A cohort study of a broad spectrum of persons at risk for developing the outcome (e.g., target disease, work status). The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who is masked to the presence of the risk factor. Study results allow calculation of measures of prognostic accuracy.</p>
<p><em>Class II</em></p>
<p>A case-control study of a broad spectrum of persons with the condition compared to a broad spectrum of controls or a cohort study of a broad spectrum of persons at risk for the outcome (e.g., target disease, work status) where the data was collected retrospectively. The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who is masked to the presence of the risk factor. Study results allow calculation of measures of prognostic accuracy.</p>
<p><em>Class III</em></p>
<p>A case-control study or a cohort study where either the persons with the condition or the controls are of a narrow spectrum where the data was collected retrospectively. The outcome is defined by an acceptable reference standard for case definition. The outcome is objective or measured by an observer who did not determine the presence of the risk factor. Study results allow calculation of measures of a prognostic accuracy.</p>
<p><em>Class IV</em></p>
<p>Studies not meeting Class I, II, or III criteria, including consensus, expert opinion, or a case report.</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Each article was classified according to the American Academy of Neurology's (AAN's) classification schemes for therapeutic (2011) and prognostic (2004) articles (see the "Rating Scheme for the Strength of the Evidence" field). Table e-1 in the data supplement (see the "Availability of Companion Documents" field) presents studies rated above Class IV (with one exception).</p>
<p>Many included studies lacked generalizability because patients, while representing a typical clinical spectrum, were preselected for surgery on the basis of tests other than the ones being studied. In these studies, the panel upgraded or downgraded certain therapeutic and prognostic conclusions using the formal AAN-modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (see tables e-2 and e-3 in the data supplement [see the "Availability of Companion Documents" field]).</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>In November 2010, the American Academy of Neurology (AAN) Guideline Development, Dissemination, and Implementation Subcommittee formed a panel of experts to develop this guideline according to the processes outlined in the 2004 AAN process manual, with 2 exceptions: the 2011 AAN process manual was used in the approach to developing conclusions and the therapeutic classification of evidence scheme subsequently updated from the 2011 AAN process manual was used (see the "Availability of Companion Documents" field).</p>
<p>The panel systematically reviewed the literature regarding the diagnosis and treatment of idiopathic normal pressure hydrocephalus (iNPH). The panel asked 2 questions:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>What is the efficacy of ventricular shunting for iNPH (therapeutic question)? </li>
    <li>Are there reliable clinical or laboratory predictors of a successful outcome of shunting (prognostic question) (efficacy and successful outcome both defined as a persistent, objectively demonstrable, and clinically meaningful improvement after shunting)? </li>
</ol>
<p>The panel linked recommendations directly to the evidence (see the "Rating Scheme for the Strength of the Recommendations" field).</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Classification of Recommendations</span></strong></p>
<p><strong>A</strong> = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>C</strong> = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">*In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>The American Association of Neurological Surgeons and the Congress of Neurological Surgeons affirm the educational content of this document.</p>
<p>Drafts of the guideline have been reviewed by at least 3 American Academy of Neurology (AAN) committees, a network of neurologists, <em>Neurology</em> peer reviewers, and representatives from related fields.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Shunting is possibly effective in patients with idiopathic normal pressure hydrocephalus (iNPH), with a 96% chance of subjective improvement, and a 83% chance improvement on the timed walk test at 6 months.</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Shunting is associated with potential morbidity and mortality. One review found a pooled mean shunt complication rate of 38% and an overall combined rate of permanent neurologic deficit and death of 6%. Another publication reported mortality rates between 5% and 15% for the shunting procedure. In the recently reported SINPHONI multicenter trial, 22% of shunted patients experienced significant adverse events (AEs). In addition to the costs of hospitalization and surgery, patients with implanted shunts are at risk of shunt failure, ventriculitis, and shunt infections. The prolonged lumbar drainage diagnostic procedure is associated with a risk of meningitis and death of 1.8%&ndash;3.6% and 0.2%, respectively. Several more recent studies describe complication rates of 15% to 28%.</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Clinical practice guidelines, practice advisories, systematic reviews, and other guidance published by the American Academy of Neurology (AAN) and its affiliates are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new evidence may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. The AAN provides this information on an "as is" basis and makes no warranty, expressed or implied, regarding the information. The AAN specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. The AAN assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions. </li>
    <li>It should be recognized that the use of ventricular shunting for idiopathic normal pressure hydrocephalus (iNPH) is based largely on uncontrolled observational studies of clinical response. </li>
</ul></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Patient Resources</p>
                    <p>Quick Reference Guides/Physician Guides</p>
                    <p>Resources</p>
                    <p>Slide Presentation</p>
                    <p>Staff Training/Competency Material</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Patient-centeredness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2015 Dec 8;85(23):2063-71. [40 references] <a href="https://web.archive.org/web/20180713063019/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26644048" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2015 Dec 8</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American Academy of Neurology - Medical Specialty Society</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>This guideline was developed with financial support from the American Academy of Neurology (AAN). Authors who serve as AAN subcommittee members or methodologists were reimbursed by the AAN for expenses related to travel to subcommittee meetings where drafts of manuscripts were reviewed.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Guideline Authors</em>: John J. Halperin, MD; Roger Kurlan, MD; Jason M. Schwalb, MD; Michael D. Cusimano, MD, PhD, FRCSC; Gary Gronseth, MD; David Gloss, MD</p>
<p><em>Guideline Development, Dissemination, and Implementation Subcommittee Members</em>: Cynthia Harden, MD (<em>Chair</em>); Steven R. Mess&eacute;, MD (<em>Co-Vice-Chair</em>); Sonja Potrebic, MD, PhD (<em>Co-Vice-Chair</em>); Eric J. Ashman, MD, FAAN; Richard L. Barbano, MD, PhD, FAAN; Brian Callaghan, MD; Jane Chan, MD, FAAN; Diane Donley, MD; Richard M. Dubinsky, MD, MPH, FAAN; Terry Fife, MD, FAAN; Jeffrey Fletcher, MD; Michael Haboubi, MD; John J. Halperin, MD, FAAN; Yolanda Holler, MD; Andres M. Kanner, MD; Annette M. Langer-Gould, MD, PhD; Jason Lazarou, MD; Nicole Licking, DO; David Michelson, MD; Pushpa Narayanaswami, MBBS, DM, FAAN; Maryam Oskoui, MD; Richard Popwell, Jr., MD; Tamara Pringsheim, MD; Alejandro A. Rabinstein, MD, FAAN; Alexander Rae-Grant, MD; Anant Shenoy, MD; Kevin Sheth, MD, FAHA; Kelly Sullivan, PhD; Jonathan P. Hosey, MD, FAAN (<em>Ex-Officio</em>); Stephen Ashwal, MD, FAAN (<em>Ex-Officio</em>); Deborah Hirtz, MD, FAAN (<em>Ex-Officio</em>); Jacqueline French, MD, FAAN (<em>AAN Guideline Historian, Ex-Officio, Voting</em>)</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Conflict of Interest</span></strong></p>
<p>The American Academy of Neurology (AAN) is committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. The AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects. Drafts of the guideline have been reviewed by at least 3 AAN committees, a network of neurologists, <em>Neurology</em> peer reviewers, and representatives from related fields. The AAN Guideline Author Conflict of Interest Policy can be viewed at <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.aan.com" title="AAN Web site">www.aan.com</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. For complete information on this process, access the 2004 AAN process manual (see the "Availability of Companion Documents" field).</p>
<p><strong><span style="text-decoration: underline;">Disclosure</span></strong></p>
<p>J. Halperin serves on the editorial boards of <em>The Neurologist</em> and <em>ACP Smart Medicine</em>; serves on the <em>Neurology</em> journal Level of Evidence Review Team; has received honoraria for continuing medical education lectures; has received research support from the Centers for Disease Control and Prevention; and has given expert testimony and acted as witness or consultant regarding the defense of several physicians in medical malpractice cases. R. Kurlan serves as a supplement editor for <em>Neurology</em>; serves on the editorial board of <em>Tremor and Other Hyperkinetic Movements</em>; serves on the speakers bureau of Teva Pharmaceuticals; receives research support from the National Institutes of Health (NIH), Kyowa, AstraZeneca, Rhythm, and Phytopharm; and served as a consultant on a medical malpractice case related to alleged missed diagnosis of normal pressure hydrocephalus (NPH). J. Schwalb serves on the Michigan Parkinson Foundation Physician and Epilepsy Foundation Physician Advisory Board; is a member of the American Association of Neurological Surgeons Subspecialty MOC Educational Materials and the<em> Congress Quarterly </em>editorial boards; has received honoraria from Medtronic; performs shunt placements for NPH; and has received research support from the NIH and internal grants from the Henry Ford Health System Neuroscience Institute. M. Cusimano reports no disclosures relevant to the manuscript. G. Gronseth serves as an evidence-based medicine methodologist for the AAN and serves on the <em>Neurology</em> Level of Evidence editorial board. D. Gloss serves as an evidence-based medicine methodologist for the AAN and serves on the <em>Neurology </em>Level of Evidence editorial board.</p>
<p>Go to <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2f" title="Neurology Journal Web site">Neurology.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> for full disclosures.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>A list of American Academy of Neurology (AAN) guidelines, along with a link to this guideline, is available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.aan.com%2fGuidelines%2f" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response. Data supplement (e-appendices, e-references, e-tables). St. Paul (MN): American Academy of Neurology; 2015. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2fcontent%2f85%2f23%2f2063%2fsuppl%2fDC1" title="Neurology Journal Web site">Neurology Journal Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response. Podcast. St. Paul (MN): American Academy of Neurology; 2015. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2fcontent%2fsuppl%2f2015%2f12%2f05%2fWNL.0000000000002193.DC2.html" title="Neurology Journal Web site">Neurology Journal Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response. Slide presentation. St. Paul (MN): American Academy of Neurology; 2015. 52 p. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f727" title="AAN Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response. Summary of evidence-based guideline for clinicians. St. Paul (MN): American Academy of Neurology; 2015. 2 p. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fhome%2fGetGuidelineContent%2f726" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Practice guideline: idiopathic normal pressure hydrocephalus: response to shunting and predictors of response. Continuing medical education course. St. Paul (MN): American Academy of Neurology; 2015. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fcme.neurology.org%2fa%2f20538P2aiHVN" title="Neurology Journal Web site">Neurology Journal Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>American Academy of Neurology (AAN). Clinical practice guideline process manual, 2011 Ed. St. Paul (MN): American Academy of Neurology. 2011. 57 p. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fDevelopment" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Idiopathic normal pressure hydrocephalus. Summary of evidence-based guideline for patients and their families. St. Paul (MN): American Academy of Neurology; 2015. 2 p. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f729" title="AAN Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Treating idiopathic normal pressure hydrocephalus: for patients. Video. St. Paul (MN): American Academy of Neurology; 2015 Dec. Available from the <a href="/web/20180713063019/https://www.guideline.gov/Home/Disclaimer?id=49957&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f728" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713063019im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul>
<p class="Note">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on March 18, 2016. The information was not verified by the guideline developer. </p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the American Academy of Neurology.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713063019/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180713063019/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180713063019/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713063019/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713063019/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713063019/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713063019/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713063019/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180713063019/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180713063019/https://www.guideline.gov/disclaimer?id=49957&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180713063019/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180713063019/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180713063019/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180713063019/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180713063019/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180713063019/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180713063019/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180713063019/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180713063019/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180713063019/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180713063019/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180713063019/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180713063019/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180713063019/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180713063019im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180713063019/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180713063019/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180713063019js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180713063019js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 06:30:19 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 16:39:49 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 68.957 (3)
  esindex: 0.008
  captures_list: 96.677
  CDXLines.iter: 13.316 (3)
  PetaboxLoader3.datanode: 60.135 (4)
  exclusion.robots: 0.176
  exclusion.robots.policy: 0.165
  RedisCDXSource: 11.31
  PetaboxLoader3.resolve: 71.927
  load_resource: 173.991
-->